Mini review · 31 May 2023
Review articlePublished 3 Jul 2020
Psychopharmacological treatment of Delirium in patients who are COVID-19+
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The scale and speed of the COVID-19 pandemic has been devastating both to patients and healthcare systems globally. This article provides concise and accessible information regarding well known pharmacological treatments for delirium in patients who are COVID+. It draws from the experience from clinicians in Italy, which was the initial epicentre of the outbreak in Europe. The agents reviewed here provide effects, side effects and interactions with other medications which are commonly used to treat patients, including antiviral agents. In conclusion, clinicians should recognise and treat delirium promptly in COVID+ patients given its potential to alleviate distress in patients, and allow for healthcare systems not to be unduly distracted by patients who present with delirium and agitation.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Psychiatry and Neuroscience.
Letter · 27 May 2023
Functional neurological disorder’s financial burden
Commentary · 27 May 2023
Examining a mechanism for the control of neuroinflammation via mindful music listening
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Psychiatry and Neuroscience
- SubjectMental Health and Psychology
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Fabrizio Pavone M.d.”
- BylineArticles whose byline prints “Andrea Fagiolini M.d.”
- BylineArticles whose byline prints “Stefano Gelati M.d.”
- BylineArticles whose byline prints “David K Ho M.d.”
